CD8A and neoplasm: IFN-I can have many positive effects on antitumor immunity, including increasing the presentation of tumor-associated antigens [50], suppressing the activity of protumorigenic Tregs and/or myeloid-derived suppressor cells [51], and improving effector CD8+ T-cell and Th1 function [29, 52].